Core Viewpoint - The company, Jinxin Reproductive Medicine (01951.HK), anticipates a loss of up to RMB 1.09 billion in the first half of 2025, following a profit of approximately RMB 190 million in the first half of 2024. This loss is primarily attributed to impairment and provisions related to goodwill, intangible assets, and other financial assets concerning its operations in the United States and Laos [1]. Financial Performance - The expected loss for the first half of 2025 is projected to be no more than RMB 1.09 billion [1]. - The company reported a profit of around RMB 190 million for the first half of 2024 [1]. Impairment and Provisions - The anticipated loss is mainly due to the recognition of impairment and provisions for certain goodwill, intangible assets, and other financial assets [1]. - The company has conducted a careful assessment of its operational and financial performance, as well as the future prospects of its business, to determine the necessity and extent of the impairments and provisions [1]. - The actual amounts for impairment and provisions will require further evaluation by the company before they can be finalized [1].

Group 1 - The company Jin Xin Reproductive (01951) announced the appointment of Mr. Dong Yang as the acting Chief Financial Officer effective immediately [1] - Mr. Dong will oversee the group's financial management, business development, operations, and other related duties assigned by the group [1]

Core Viewpoint - The company, Jinxin Reproductive Medicine (01951), anticipates a loss of no more than RMB 1.09 billion in the first half of 2025, following a profit of approximately RMB 190 million in the first half of 2024, primarily due to impairment and provisions related to goodwill, intangible assets, and other financial assets in its operations in the United States and Laos [1] Group 1 - The expected loss for the first half of 2025 is mainly attributed to the recognition of impairment and provisions for certain goodwill, intangible assets, and other financial assets [1] - The company has conducted a careful assessment of its operational and financial performance, as well as the future prospects of its business, to determine the need and extent of the impairment and provisions [1] - The actual amounts of impairment and provisions will require further evaluation by the company before they can be finalized [1] Group 2 - The company believes that the impairment and provisions in the first half of 2025 will not have a significant adverse impact on its overall business operations and cash flow, as they are primarily one-time non-cash items [1] - Despite challenges posed by the macroeconomic and industry conditions in the first half of 2025, the company remains confident in the long-term prospects of the industry and its growth due to its solid industry foundation and ongoing efforts to enhance clinical outcomes, patient care, and service quality [1]

Core Viewpoint - Jinxin Fertility (01951) has appointed Mr. Dong Yang as the acting Chief Financial Officer, effective immediately from the date of the announcement [1] Group 1 - Mr. Dong Yang will oversee the group's financial management, business development, and operations [1] - The appointment includes other related duties as assigned by the group [1]

Core Viewpoint - The company expects to incur a loss of no more than RMB 1.09 billion in the first half of 2025, following a profit of approximately RMB 190 million in the first half of 2024, primarily due to impairment and provisions related to goodwill, intangible assets, and other financial assets in its operations in the US and Laos [1] Financial Performance - The anticipated loss for the first half of 2025 is attributed to the recognition of impairment and provisions for certain assets [1] - The actual amount of impairment and provisions will be subject to further assessment by the company [1] Business Outlook - The company believes that the impairments and provisions will not have a significant adverse impact on overall business operations and cash flow, as they are mainly one-time non-cash items [1] - Despite challenges posed by macroeconomic and industry conditions in the first half of 2025, the company remains confident in the long-term prospects for the industry and its growth due to solid industry fundamentals and supportive national policies [1] - The company is committed to improving clinical outcomes, patient care, and service quality, which reinforces its optimistic outlook for future growth [1]

錦 欣 生 殖 醫 療 集 團 有 限 公 司* 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Jinxin Fertility Group Limited 董陽 香港，2025年8月8日 （根據開曼群島法律註冊成立的有限公司） （股份代號：1951） 於本公告日期，本公司董事會包括執行董事John G. Wilcox醫生、董陽先生、呂蓉女士及耿麗 紅博士；主席兼非執行董事鍾勇先生，以及非執行董事方敏先生、胡喆女士及嚴曉晴女士； 及獨立非執行董事莊一強博士、李建偉先生、王嘯波先生及葉長青先生。 董事會會議日期 * 僅供識別 承董事會命 錦欣生殖醫療集團有限公司* 首席執行官兼執行董事 錦欣生殖醫療集團有限公司*（「本公司」，連同其附屬公司，統稱「本集團」）董 事（「董事」）會（「董事會」）謹此宣佈，本公司謹訂於2025年8月25日（星期一）舉 行董事會會議，藉以（其中包括）考慮及批准本集團截至2025年6月30日止六個 月的中期業績及其發佈。 ...

（根據開曼群島法律註冊成立的有限公司） （股份代號：1951） Jinxin Fertility Group Limited 錦 欣 生 殖 醫 療 集 團 有 限 公 司* 董事名單與其角色和職能 錦欣生殖醫療集團有限公司董事會（「董事會」）成員載列如下： 執行董事 John G. Wilcox醫生 董陽先生 （首席執行官及代理首席財務官） 呂蓉女士 （聯席首席執行官） 耿麗紅博士 非執行董事 鍾勇先生 （主席） 方敏先生 胡喆女士 嚴曉晴女士 獨立非執行董事 – 2 – – 1 – 董事會已成立五個委員會，各委員會成員載列如下： | 董事委員會 | | | | | 醫療品質控制與 | | --- | --- | --- | --- | --- | --- | | | 審核及風險管理 | | | | 科研發展 | | 董事 | 委員會 | 薪酬委員會 | 提名委員會 | 戰略決策委員會 | 委員會 | | John G. Wilcox醫生 | — | — | M | M | M | | 董陽先生 | — | M | — | M | — | | 呂蓉女士 | — | — | M | — | — | | 耿麗紅 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告的全部或任何部份內容所產生 或因依賴該等內容而引致的任何損失承擔任何責任。 Jinxin Fertility Group Limited 錦 欣 生 殖 醫 療 集 團 有 限 公 司* 委任代理首席財務官 本公告由錦欣生殖醫療集團有限公司*（「本公司」，連同其附屬公司，統稱為「本 集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及 香港法例第571章證券及期貨條例第XIVA部項下內幕消息條文（定義見上市規則） 刊發。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資 者，根據對本集團截至二零二五年六月三十日止六個月（「二零二五年上半年」） 的未經審核綜合管理賬目（按照國際財務報告準則編製）的初步評估及董事會 目前可得資料，預期本集團將於二零二五年上半年錄得虧損不超過人民幣1,090 百萬元，而本集團於截至二零二四年六月三十日止六個月（「二零二四年上半年」） 則錄得純利約人民幣190百萬元。此虧損乃主要由於就有關本集團 ...

Group 1 - The top three companies with the highest short positions as of August 1 are WuXi AppTec (02359), CATL (03750), and Luye Pharma (02186), with short ratios of 20.99%, 15.26%, and 13.94% respectively [1][2] - The companies with the largest absolute increase in short positions are ZTE Corporation (00763), Jinxin Fertility (01951), and Vanke Enterprises (02202), with increases of 2.92%, 2.49%, and 2.44% respectively [1][2] - The companies with the largest absolute decrease in short positions are UBTECH Robotics (09880), Kelai Ying (06821), and Mingyuan Cloud (00909), with decreases of -2.34%, -1.30%, and -1.28% respectively [1][3] Group 2 - The top ten companies with the highest short ratios include WuXi AppTec (02359) at 20.99%, CATL (03750) at 15.26%, and Luye Pharma (02186) at 13.94% [2] - The companies with the most significant increase in short ratios include ZTE Corporation (00763) from 8.47% to 11.39%, Jinxin Fertility (01951) from 7.94% to 10.43%, and Vanke Enterprises (02202) from 9.81% to 12.26% [2] - The companies with the most significant decrease in short ratios include UBTECH Robotics (09880) from 3.97% to 1.63%, Kelai Ying (06821) from 7.30% to 6.01%, and Mingyuan Cloud (00909) from 4.33% to 3.04% [3][4]

本文源自：金融界 作者：行情君 8月4日，锦欣生殖(01951)盘中下跌4.19%，截至15:45，报3.2元/股，成交3.0亿元。 锦欣生殖医疗集团有限公司是中美领先的辅助生殖服务机构，拥有和经营多家医院和医疗中心，主要提 供辅助生殖服务及相关治疗。根据弗若斯特沙利文报告，2018年，公司在中国辅助生殖服务市场中排名 第三，进行了20,958个体外受精取卵周期，市场份额约为3.1%，在非国有辅助生殖服务机构中排名第 一。 截至2024年年报，锦欣生殖营业总收入28.12亿元、净利润2.83亿元。 ...